Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
Antibody
Quantitative anti-spike antibody
SARS-CoV-2
Serology
Vaccine
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
21
03
2021
revised:
23
05
2021
accepted:
25
05
2021
pubmed:
11
6
2021
medline:
16
10
2021
entrez:
10
6
2021
Statut:
ppublish
Résumé
We investigated determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike IgG responses in healthcare workers (HCWs) following one or two doses of Pfizer-BioNTech or Oxford-AstraZeneca vaccines. HCWs participating in regular SARS-CoV-2 PCR and antibody testing were invited for serological testing prior to first and second vaccination, and 4 weeks post-vaccination if receiving a 12-week dosing interval. Quantitative post-vaccination anti-spike antibody responses were measured using the Abbott SARS-CoV-2 IgG II Quant assay (detection threshold: ≥50 AU/mL). We used multivariable logistic regression to identify predictors of seropositivity and generalized additive models to track antibody responses over time. 3570/3610 HCWs (98.9%) were seropositive >14 days post first vaccination and prior to second vaccination: 2706/2720 (99.5%) were seropositive after the Pfizer-BioNTech and 864/890 (97.1%) following the Oxford-AstraZeneca vaccines. Previously infected and younger HCWs were more likely to test seropositive post first vaccination, with no evidence of differences by sex or ethnicity. All 470 HCWs tested >14 days after the second vaccination were seropositive. Quantitative antibody responses were higher after previous infection: median (IQR) >21 days post first Pfizer-BioNTech 14 604 (7644-22 291) AU/mL versus 1028 (564-1985) AU/mL without prior infection (p < 0.001). Oxford-AstraZeneca vaccine recipients had lower readings post first dose than Pfizer-BioNTech recipients, with and without previous infection, 10 095 (5354-17 096) and 435 (203-962) AU/mL respectively (both p < 0.001 versus Pfizer-BioNTech). Antibody responses >21 days post second Pfizer vaccination in those not previously infected, 10 058 (6408-15 582) AU/mL, were similar to those after prior infection followed by one vaccine dose. SARS-CoV-2 vaccination leads to detectable anti-spike antibodies in nearly all adult HCWs. Whether differences in response impact vaccine efficacy needs further study.
Identifiants
pubmed: 34111577
pii: S1198-743X(21)00289-5
doi: 10.1016/j.cmi.2021.05.041
pmc: PMC8180449
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
ChAdOx1 nCoV-19
B5S3K2V0G8
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1516.e7-1516.e14Subventions
Organisme : Medical Research Council
ID : MR/N00065X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V001329/1
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Elife. 2020 Aug 21;9:
pubmed: 32820721
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Clin Infect Dis. 2022 Apr 9;74(7):1208-1219
pubmed: 34216472
N Engl J Med. 2021 May 20;384(20):1959-1961
pubmed: 33755375
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855